Home treatment with Carfilzomib for Multiple Myeloma patients
A Prospective Clinical, Mixed-method Study Exploring Patient and Health Care Perspectives
This study tests if giving Multiple Myeloma patients their treatment at home with Carfilzomib can help them avoid hospital visits and stay safe from infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Odense University Hospital Academic / other |
| Locations | 1 site (Odense) |
| Trial ID | NCT05620238 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of administering Carfilzomib, a treatment for relapsed Multiple Myeloma, in a home setting to reduce hospital visits. Patients will receive intravenous infusions in the hospital on specific days, but will be educated to self-administer the drug at home on other days. This approach seeks to minimize the risk of hospital-acquired infections and decrease the burden of transportation for patients. The study will involve patients who have already begun treatment in an outpatient clinic and can communicate in Danish.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with Multiple Myeloma who are currently being treated with Carfilzomib and have completed at least one treatment cycle.
Not a fit: Patients receiving trial medication or those who do not speak Danish may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the quality of life for patients by reducing hospital visits and associated risks.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in reducing hospital visits for other treatments, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with Multiple Myeloma in treatment with Carfilzomib * Patients must have received a minimum of one treatment cycle in the outpatient clinic * Patients must understand and speak Danish Exclusion Criteria: * Patients receiving trial medication
Where this trial is running
Odense
- Odense University Hospital — Odense, Denmark (Recruiting)
Study contacts
- Study coordinator: Jannie Kirkegaard, RN
- Email: jannie.kirkegaard@rsyd.dk
- Phone: +45 29648494
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.